A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

NCT07105592 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Nimotuzumab+Adebrelimab+Chemotherapy

Sponsor

Fudan University